# Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

> **NCT03299660** · PHASE2 · COMPLETED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 37 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** 5 Fluorouracil
- **DRUG:** Capecitabine Pill
- **RADIATION:** Radiotherapy
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT03299660
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299660, "Avelumab With Chemoradiation in Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03299660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*